Independent directory Public ClinicalTrials.gov records United States
Clear filters

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Nov 18, 2026, 8:48 PM EST

All trial information on this site comes from the official ClinicalTrials.gov public API (clinicaltrials.gov/api/v2), run by the U.S. National Library of Medicine. We only display that public information; we do not add opinions, endorsements, or any other intent. Always review the official ClinicalTrials.gov record for the latest information.

Showing 73–96 of 2,486 matching trials from the live ClinicalTrials.gov search.
Terminated Phase 1Phase 2 Interventional Results available

Study to Assess AFM24 in Advanced Solid Cancers

NCT04259450
Conditions
Advanced Solid Tumor
Interventions
14 mg AFM24, 40 mg AFM24, 80 mg AFM24, 160 mg AFM24, 320 mg AFM24, 480 mg AFM24, 720 mg AFM24
Drug
Lead sponsor
Affimed GmbH
Industry
Eligibility
18 Years and older
Enrollment
85 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020 – 2024
U.S. locations
2
States / cities
Los Angeles, California • Boston, Massachusetts
Conditions
Platinum-resistant Ovarian Cancer, Testicular Cancer, Endometrial Cancer
Interventions
CTIM-76
Drug
Lead sponsor
Context Therapeutics Inc.
Industry
Eligibility
18 Years and older
Enrollment
156 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2024 – 2028
U.S. locations
14
States / cities
Little Rock, Arkansas • Beverly Hills, California • Denver, Colorado + 11 more
Conditions
Unspecified Adult Solid Tumor, Protocol Specific
Interventions
triapine
Drug
Lead sponsor
Vion Pharmaceuticals
Industry
Eligibility
18 Years and older
Healthy volunteers
Healthy volunteers not accepted
Timeline
2000 – 2008
U.S. locations
1
States / cities
The Bronx, New York
Conditions
Locally Advanced or Metastatic Solid Tumors
Interventions
LUNA18, Cetuximab
Drug
Lead sponsor
Chugai Pharmaceutical
Industry
Eligibility
18 Years and older
Enrollment
128 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2025
U.S. locations
13
States / cities
Davis, California • Boston, Massachusetts • Detroit, Michigan + 9 more
Conditions
Solid Tumor
Interventions
PEGPH20
Drug
Lead sponsor
Halozyme Therapeutics
Industry
Eligibility
18 Years and older
Enrollment
27 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2010 – 2014
U.S. locations
5
States / cities
Scottsdale, Arizona • Encinitas, California • Detroit, Michigan + 1 more
Conditions
Cancer, Lymphoma
Interventions
XL844, Gemcitabine
Drug
Lead sponsor
Exelixis
Industry
Eligibility
18 Years and older
Enrollment
28 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2007 – 2008
U.S. locations
2
States / cities
New York, New York • Houston, Texas
Conditions
Advanced Solid Tumor, Metastatic Solid Tumor
Interventions
JZP898, Pembrolizumab
Drug
Lead sponsor
Jazz Pharmaceuticals
Industry
Eligibility
18 Years and older
Enrollment
177 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2023 – 2028
U.S. locations
10
States / cities
Encinitas, California • Fresno, California • Denver, Colorado + 7 more
Conditions
Unspecified Adult Solid Tumor, Protocol Specific
Interventions
bortezomib, vorinostat
Drug
Lead sponsor
National Cancer Institute (NCI)
NIH
Eligibility
18 Years and older
Enrollment
66 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
Started 2005
U.S. locations
1
States / cities
Madison, Wisconsin
Conditions
Advanced Solid Tumors
Interventions
IMP7068
Drug
Lead sponsor
Impact Therapeutics, Inc.
Industry
Eligibility
18 Years and older
Enrollment
350 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2023
U.S. locations
7
States / cities
Atlanta, Georgia • Fairway, Kansas • Louisville, Kentucky + 4 more
Conditions
Melanoma (Skin), Non Small Cell Lung Cancer, Breast Cancer
Interventions
ENV-501
Biological
Lead sponsor
Hummingbird Bioscience
Industry
Eligibility
18 Years and older
Enrollment
180 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2025 – 2027
U.S. locations
5
States / cities
La Jolla, California • Indianapolis, Indiana • Farmington Hills, Michigan + 2 more
Conditions
Advanced Solid Tumor, High Grade Serous Adenocarcinoma of Ovary, Squamous Non-small-cell Lung Cancer, Triple Negative Breast Cancer, Head and Neck Squamous Cell Carcinoma, Ovarian Carcinosarcoma, Uterine Carcinosarcoma, Uterine Serous Carcinoma, Endometrium Cancer, Chromosomal Instability
Interventions
VLS-1488
Drug
Lead sponsor
Volastra Therapeutics, Inc.
Industry
Eligibility
18 Years and older
Enrollment
200 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2023 – 2026
U.S. locations
14
States / cities
Los Angeles, California • Newport Beach, California • Aurora, Colorado + 11 more
Conditions
Advanced Solid Tumors, Advanced Recurrent Ovarian Tumors
Interventions
MEDI3617, Bevacizumab, Paclitaxel, Carboplatin
Drug
Lead sponsor
MedImmune LLC
Industry
Eligibility
18 Years to 99 Years
Enrollment
162 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2010 – 2015
U.S. locations
10
States / cities
Los Angeles, California • Stanford, California • Lafayette, Indiana + 7 more
Conditions
Advanced Solid Tumors, Malignant Neoplasm
Interventions
MK-3120
Biological
Lead sponsor
Merck Sharp & Dohme LLC
Industry
Eligibility
18 Years and older
Enrollment
270 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2025 – 2031
U.S. locations
7
States / cities
Birmingham, Alabama • Miami, Florida • Hackensack, New Jersey + 4 more
Conditions
Solid Tumors
Interventions
JAB-30355
Drug
Lead sponsor
Jacobio Pharmaceuticals Co., Ltd.
Industry
Eligibility
18 Years and older
Enrollment
144 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2024 – 2027
U.S. locations
7
States / cities
Denver, Colorado • Lake Mary, Florida • St Louis, Missouri + 4 more
Conditions
Advanced Solid Tumor, Metastatic Solid Tumor
Interventions
JZP341
Drug
Lead sponsor
Jazz Pharmaceuticals
Industry
Eligibility
18 Years and older
Enrollment
12 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2022 – 2024
U.S. locations
8
States / cities
Denver, Colorado • Sarasota, Florida • Baltimore, Maryland + 5 more
Conditions
Unspecified Adult Solid Tumor, Protocol Specific
Interventions
laboratory biomarker analysis, pharmacological study, recombinant albumin fusion protein sEphB4-HSA
Other · Biological
Lead sponsor
University of Southern California
Other
Eligibility
18 Years and older
Enrollment
102 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2012 – 2019
U.S. locations
1
States / cities
Los Angeles, California
Conditions
Advanced Solid Tumors
Interventions
Treatment with ARQ 197 in combination with gemcitabine
Drug
Lead sponsor
ArQule, Inc., a subsidiary of Merck Sharp & Dohme LLC, a subsidiary of Merck & Co., Inc. (Rahway, NJ USA)
Industry
Eligibility
18 Years and older
Enrollment
74 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2009 – 2011
U.S. locations
4
States / cities
Atlanta, Georgia • Oklahoma City, Oklahoma • Nashville, Tennessee + 1 more
Conditions
Advanced Solid Tumor
Interventions
M9466, Irinotecan, Folinic acid, Fluorouracil (5-FU), Bevacizumab, Granulocyte colony stimulating factor (G-CSF)
Drug
Lead sponsor
EMD Serono Research & Development Institute, Inc.
Industry
Eligibility
18 Years and older
Enrollment
3 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2024 – 2025
U.S. locations
4
States / cities
Denver, Colorado • Pennington, New Jersey • Nashville, Tennessee + 1 more
Conditions
Advanced Solid Tumors
Interventions
ABI-011
Drug
Lead sponsor
Celgene
Industry
Eligibility
18 Years and older
Enrollment
60 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2011
U.S. locations
2
States / cities
Detroit, Michigan • San Antonio, Texas
Conditions
Advanced Cancer
Interventions
ZIO-201-T and doxorubicin
Drug
Lead sponsor
Alaunos Therapeutics
Industry
Eligibility
18 Years and older
Enrollment
30 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2008 – 2009
U.S. locations
2
States / cities
Santa Monica, California • Houston, Texas
Conditions
Tumor, Solid
Interventions
BDB001
Drug
Lead sponsor
Eikon Therapeutics
Industry
Eligibility
18 Years and older
Enrollment
1 participant
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2023
U.S. locations
1
States / cities
Houston, Texas
Conditions
Neoplasms
Interventions
Epothilone D (KOS-862)
Drug
Lead sponsor
Bristol-Myers Squibb
Industry
Eligibility
18 Years to 85 Years
Enrollment
45 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2001 – 2003
U.S. locations
1
States / cities
Los Angeles, California
Conditions
Advanced Solid Tumors, Merkel Cell Carcinoma
Interventions
FF-10850 Topotecan Liposome Injection
Drug
Lead sponsor
Fujifilm Pharmaceuticals U.S.A., Inc.
Industry
Eligibility
18 Years and older
Enrollment
96 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019 – 2027
U.S. locations
7
States / cities
Scottsdale, Arizona • Denver, Colorado • Boston, Massachusetts + 4 more
Conditions
Solid Tumors, Metastatic Tumors
Interventions
OTS167IV
Drug
Lead sponsor
OncoTherapy Science, Inc.
Industry
Eligibility
18 Years and older
Enrollment
32 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2013 – 2016
U.S. locations
1
States / cities
Chicago, Illinois